Enterprise Associates 17 New Acquires 207,100 Shares of Korro Bio (NASDAQ:KRRO) Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Enterprise Associates 17 New acquired 207,100 shares of the stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the purchase, the insider directly owned 1,297,893 shares in the company, valued at $14,419,591.23. The trade was a 18.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Korro Bio Stock Performance

Shares of KRRO stock opened at $12.80 on Friday. Korro Bio, Inc. has a 52-week low of $5.20 and a 52-week high of $55.89. The stock has a market cap of $120.58 million, a price-to-earnings ratio of -1.03 and a beta of 2.98. The firm’s 50-day moving average is $10.99 and its 200-day moving average is $20.18.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($5.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.93) by ($3.39). The business had revenue of $1.29 million for the quarter, compared to the consensus estimate of $0.43 million. Korro Bio had a negative return on equity of 99.63% and a negative net margin of 1,834.48%. Sell-side analysts predict that Korro Bio, Inc. will post -9.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Korro Bio

A number of large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new position in shares of Korro Bio during the third quarter worth approximately $39,000. CWM LLC boosted its stake in Korro Bio by 391.4% in the 3rd quarter. CWM LLC now owns 2,693 shares of the company’s stock valued at $129,000 after purchasing an additional 2,145 shares during the period. Wells Fargo & Company MN boosted its stake in Korro Bio by 45.5% in the 4th quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after purchasing an additional 2,352 shares during the period. PNC Financial Services Group Inc. acquired a new position in Korro Bio in the 3rd quarter valued at $140,000. Finally, Millennium Management LLC increased its position in Korro Bio by 1.8% during the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock worth $12,467,000 after buying an additional 4,650 shares during the period. Institutional investors own 13.18% of the company’s stock.

Korro Bio News Roundup

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target, providing a prominent analyst endorsement that can attract momentum and institutional buyers. Read More.
• Positive Sentiment: Multiple major shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed large purchases (~207,100 shares at ~$11.11 each), signaling strong insider/large‑holder conviction and providing buying support. Read More.
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for hyperammonemia, is advancing a GalNAc oligo candidate for AAT deficiency (on track to nominate in Q2 2026), and closed an oversubscribed $85M private placement, which management says extends cash runway into H2 2028 — materially reducing near‑term financing risk. Read More.
• Neutral Sentiment: Revenue for Q4 modestly exceeded expectations ($1.29M vs. ~ $0.42M est.), but the amount is very small relative to R&D and operating burn, so near‑term profit improvement is limited. Read More.
• Negative Sentiment: Quarterly and annual results show heavy write‑downs and operating losses: Q4 EPS was a ($5.32) miss vs. consensus (~($1.93)), and full‑year net loss widened (reported ~$117.3M) driven by non‑cash impairment charges — highlighting high execution risk and potential for volatility if clinical progress stalls. Read More. Read More.

Analyst Ratings Changes

A number of research firms recently weighed in on KRRO. Chardan Capital raised Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Thursday, January 29th. Cantor Fitzgerald raised their price target on Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Friday. JonesTrading cut shares of Korro Bio from a “buy” rating to a “hold” rating in a research report on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a report on Friday, January 9th. Finally, William Blair raised shares of Korro Bio from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $44.50.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.